Loading...

Fangzhou Inc.

6086.HK•HKSE
Consumer Cyclical
Drug Manufacturers - General
HK$3.88
HK$0.09(2.37%)

Fangzhou Inc. (6086.HK) Stock Overview

Explore Fangzhou Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 70.8/100

Key Financials

Market Cap5.2B
P/E Ratio-5.37
EPS (TTM)$-0.96
ROE0.93%
Fundamental Analysis

AI Price Forecasts

1 Week$4.02
1 Month$4.75
3 Months$3.77
1 Year Target$7.09

6086.HK Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Fangzhou Inc. (6086.HK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 54.17, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $7.09.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -5.37 and a market capitalization of 5.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

54.17RSI (14)
-0.04MACD
36.54ADX
Stats data is not available for 6086.HKStats details for 6086.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 6086.HKAnalyst Recommendations details for 6086.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Fangzhou Inc. provides online chronic disease management services in China. The company provides services through online chronic disease management platform to address the needs of patients with chronic disease, such as hypertension, cardiovascular and respiratory chronic diseases. It offers H2H services, including online medical consultation services, e-prescription, and prescription refill services through mobile application; and healthcare products through online retail pharmacy service platform, as well as operates hospitals and offline pharmacies. The company was founded in 2015 and is based in Guangzhou, China.

CEO

Fangmin Xie

Employees

488

Headquarters

Building S, Kehui Jingu, Guangzhou

Founded

1970

Frequently Asked Questions

;